GlaxoSmithKline said that it has formed a strategic alliance to develop aptamer therapeutics with the privately-held US biopharmaceutical company, Archemix Corp. The deal is valued at up to $1.4 billion and will focus on developing products to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. It was announced on 23 December 2008.
